Success Metrics

Clinical Success Rate
69.2%

Based on 9 completed trials

Completion Rate
69%(9/13)
Active Trials
0(0%)
Results Posted
11%(1 trials)
Terminated
4(29%)

Phase Distribution

Ph phase_4
4
29%
Ph not_applicable
3
21%
Ph phase_3
6
43%

Phase Distribution

0

Early Stage

0

Mid Stage

10

Late Stage

Phase Distribution13 total trials
Phase 3Large-scale testing
6(46.2%)
Phase 4Post-market surveillance
4(30.8%)
N/ANon-phased studies
3(23.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

69.2%

9 of 13 finished

Non-Completion Rate

30.8%

4 ended early

Currently Active

0

trials recruiting

Total Trials

14

all time

Status Distribution
Completed(9)
Terminated(4)
Other(1)

Detailed Status

Completed9
Terminated4
unknown1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
0
Success Rate
69.2%
Most Advanced
Phase 4

Trials by Phase

Phase 36 (46.2%)
Phase 44 (30.8%)
N/A3 (23.1%)

Trials by Status

terminated429%
unknown17%
completed964%

Recent Activity

0 active trials
Showing 5 of 14
completed

An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)

NCT01498770
terminatedphase_4

The Effect of Sertindole and Risperidone on Endophenotypic Markers of Schizophrenia

NCT02021201
completedphase_4

Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients

NCT02307396
terminatedphase_3

Pharmacovigilance in Gerontopsychiatric Patients

NCT02374567
completedphase_4

Safety Study of an Antipsychotic, Sertindole, to Treat Schizophrenia

NCT00763438
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT01498770

An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)

Completed
NCT02021201Phase 4

The Effect of Sertindole and Risperidone on Endophenotypic Markers of Schizophrenia

Terminated
NCT02307396Phase 4

Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients

Completed
NCT02374567Phase 3

Pharmacovigilance in Gerontopsychiatric Patients

Terminated
NCT00763438Phase 4

Safety Study of an Antipsychotic, Sertindole, to Treat Schizophrenia

Completed
NCT00654706Phase 3

Efficacy Study Exploring the Effects on Cognition of Sertindole Versus Comparator in Patients With Schizophrenia

Completed
NCT00759460Phase 3

Study on Metabolic Parameters of Sertindole in Patients With Schizophrenia

Completed
NCT00864045Phase 3

Sertindole in Asian Patients With Schizophrenia

Completed
NCT00759421Phase 3

Exploratory Cognition Study of Sertindole in Patients With Schizophrenia

Completed
NCT00885690Not Applicable

Comparing the Effects of Sertindole and Olanzapine on Cognition (SEROLA)

Terminated
NCT00612079Not Applicable

The Effect of Sertindole on Sensory Gating and Cognition in Healthy Volunteers

Completed
NCT00629252Not Applicable

The Effect of Sertindole on Sensory Gating and Cognition in Schizophrenic Patients

Terminated
NCT00856583Phase 3

Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use

Completed
NCT00480844Phase 4

Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone

Unknown

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14